Hunter BioDiscovery
June 16, 2025
Company Presentation
Tools/Drug Development Support Tech
Founded by serial entrepreneurs and Harvard professors John Iafrate and David Weitz, Hunter BioDiscovery designed an AI-guided, high-throughput platform called FlowMatrixTM to rapidly assess drug synergy and synthetic lethality in live cells to identify novel drug combinations, discover new biologic insights, overcome drug resistance, improve therapeutic index and drug response to treat cancer.
Company HQ City:
Millbury
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2015
Lead Product in Development:
ATR combination with anti-infective for oncology indication
CEO
Arlinda Lee, PhD
Year Founded
2015
Development Phase of Lead Product
Discovery
Number of Unlicensed Products Looking for Licensing
3+
When you expect your next catalyst update?
Results of combination in mice
What is your next catalyst (value inflection) update?
July 2025
Website
https://www.hunter.bio/home
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}